Testing a new treatment for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new treatment for advanced or metastatic esophageal cancer that has not responded to previous chemotherapy. It aims to see if this treatment can help slow down the cancer or shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of a certain type of esophageal cancer (squamous cell carcinoma).
- Your cancer must have come back or spread, and you must have already had one round of chemotherapy that didn't work or stopped working.
- You need to be in fairly good health (able to do light work or be fully active).
- You must have at least one tumor that can be measured on a scan.
- You must be willing to use birth control during the study and for 8 weeks after the last dose of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
This trial tests a new drug combination (SKB500 plus other treatments) for people with advanced esophageal squamous cell carcinoma. It aims to see if the combination is safe and effective for those who have had little or no prior treatment.
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.